









Markets
/
Stocks
/
nasdaq-achv
/

Achieve Life Sciences Inc

ACHV

4.484USD

-0.256-5.39%

Market hours （ET）Quotes delayed by 15 min

222.81MMarket Cap

LossP/E TTM



Achieve Life Sciences Inc

4.484

-0.256-5.39%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Achieve Life Sciences Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Achieve Life Sciences Inc's Score

Industry at a Glance

Industry Ranking

64 / 407

Overall Ranking

174 / 4615

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

15.333

Target Price

+211.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Achieve Life Sciences Inc Highlights

StrengthsRisks

Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.

Undervalued

The company’s latest PE is -3.21, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 31.38M shares, increasing 27.96% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.15M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 7.02, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.02

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Achieve Life Sciences Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.16, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -3.21, which is -80.63% below the recent high of -0.62 and -48.67% above the recent low of -4.78.

Score

Industry at a Glance

Previous score

6.16

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 64/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 8.29, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Achieve Life Sciences Inc is 13.00, with a high of 25.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

15.333

Target Price

+211.02%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Achieve Life Sciences Inc

ACHV

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 8.90, which is higher than the Biotechnology & Medical Research industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 6.00 and the support level at 3.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.04

Change

-0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.068

Neutral

RSI(14)

58.897

Neutral

STOCH(KDJ)(9,3,3)

24.556

Sell

ATR(14)

0.422

Low Volatility

CCI(14)

-81.192

Neutral

Williams %R

67.097

Sell

TRIX(12,20)

2.005

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

4.942

Sell

MA10

4.936

Sell

MA20

4.467

Buy

MA50

3.622

Buy

MA100

3.166

Buy

MA200

3.037

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 61.40%, representing a quarter-over-quarter increase of 49.95%. The largest institutional shareholder is The Vanguard, holding a total of 2.15M shares, representing 4.21% of shares outstanding, with 17.32% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Propel Bio Management, LLC

9.85M

+301.66%

Franklin Advisers, Inc.

4.46M

+81.34%

Alyeska Investment Group, L.P.

3.50M

+732.38%

The Vanguard Group, Inc.

Star Investors

2.15M

+25.21%

Contrarian Alpha Management, L.L.C.

1.54M

+7.30%

Patrick (Callahan J. III)

1.53M

Clearline Capital LP

1.33M

Simplify Asset Management Inc

1.18M

+443.74%

Hudson Bay Capital Management LP

1.17M

Heights Capital Management, Inc.

989.51K

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 4.41, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.69. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.